1 / 2

Supplementary Figure 1

Supplementary Figure 1. A. B. C. D. b -cat (Ser675). E.

anne
Download Presentation

Supplementary Figure 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplementary Figure 1 A. B. C. D. b-cat (Ser675) E.

  2. Figure legend: Both control (GIPZ-Scrambled) and GIPZ-PAK-1 shRNAmir expressing cells were pre-treated with or without the MEK inhibitor PD98059 (PD) for 1h prior to insulin treatment. Amounts of phosphorylated PAK-1 (Thr423), PAK-1, c-Myc, cyclin D1, Ser675 phosphorylated -cat, total -cat, p-ERK, ERK and b-actin (as the loading control) were detected by Western blotting and subject to densitometric analysis (n=3). A representative blot is shown in Fig, 4C.

More Related